A61K 40/41
Vertebrate antigens
A61K40/41 (Vertebrate antigens) appears on 5,717 US grants and 13,058 published applications in this corpus.
Search patents in A61K- Granted patents
- 5,717
- Published applications
- 13,058
- Assignees
- 2,939
- Inventors
- 15,740
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 5 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 4 | 0 |
| 1993 | 6 | 0 |
| 1994 | 8 | 0 |
| 1995 | 4 | 0 |
| 1996 | 6 | 0 |
| 1997 | 17 | 0 |
| 1998 | 36 | 0 |
| 1999 | 21 | 0 |
| 2000 | 31 | 0 |
| 2001 | 32 | 17 |
| 2002 | 53 | 138 |
| 2003 | 38 | 174 |
| 2004 | 37 | 160 |
| 2005 | 26 | 124 |
| 2006 | 52 | 136 |
| 2007 | 23 | 97 |
| 2008 | 53 | 156 |
| 2009 | 51 | 151 |
| 2010 | 92 | 203 |
| 2011 | 89 | 204 |
| 2012 | 88 | 163 |
| 2013 | 110 | 191 |
| 2014 | 125 | 252 |
| 2015 | 144 | 243 |
| 2016 | 165 | 314 |
| 2017 | 161 | 463 |
| 2018 | 242 | 599 |
| 2019 | 317 | 856 |
| 2020 | 470 | 1067 |
| 2021 | 483 | 1247 |
| 2022 | 501 | 1418 |
| 2023 | 496 | 1267 |
| 2024 | 591 | 1415 |
| 2025 | 675 | 1135 |
| 2026 | 457 | 868 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells384US 6,905,681 B1Genetics Institute, Inc. · 2005
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005